Neonc Technologies Holdings Inc (NTHI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.03+5.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — EPS loss narrows toward consensus estimates: FY26 EPS -$1.35 vs -$0.85.
NeOnc aims to reduce cash operating expenses to about $10.1 million annually. The company has secured capital through Series A Preferred Stock to fund its cancer therapy pipeline. Analysts have slightly improved EPS estimates from -$1.00 to -$0.85 for FY26. Strategic partnerships could accelerate commercialization of its therapies.
NeOnc is loss-making with negative EPS of -$0.38 next quarter and -$0.85 for FY26. The stock has fallen 33% from its high and shows a high risk profile. Recent capital raises via unregistered equity dilute shareholders and signal cash stress. The company missed earnings recently and faces volatile management execution.
The market prices NeOnc near $15 per share, in line with Street median targets. This reflects expectations of continued losses and limited near-term revenue. Our view aligns with this cautious outlook given the company's unprofitable status and high risk.
Breaks if: cash operating expenses exceed $10.1 million in FY26
Focus on reducing cash operating expenses to approximately $10.1 million for the year.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. NTHI is navigating a challenging financial landscape while advancing its clinical trials, which could lead to significant future value if successful.
The market appears to have low expectations for NTHI, given its recent earnings misses and overall weak financial performance. However, the low fragility tier suggests that current pricing does not reflect extreme vulnerabilities.
Fundamentals are expected to remain volatile in the near term, with a high probability of an earnings miss. Management is focused on advancing clinical trials and maintaining expense discipline, but recent performance has been below industry peers.
The thesis hinges on the outcomes of clinical trials for NEO100 and NEO212, as well as broader sector performance influenced by leading healthcare companies. Additionally, guidance changes and macroeconomic conditions, such as employment trends, could significantly impact sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The advance of the NEO100 Phase 2a trial supports growth objectives. However, the latest earnings miss raises concerns about financial performance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS falls below -$0.85 for FY26
Breaks if: failure to deploy capital from Series A Preferred Stock by mid-2026
In the next 1 to 3 years, NTHI's performance will depend on its clinical advancements and market conditions. Not investment advice.